89bio is a clinical-stage biopharma company focused on changing the lives of patients with non-alcoholic steatohepatitis (NASH) and other liver and cardio-metabolic diseases.
With its proprietary glycoPEGylated technology, BIO89-100 has the potential to be differentiated based on robust biologic effects, a favorable tolerability profile, and a longer dosing interval.
Fibroblast growth factor 21 (FGF21), with its broad-based effects, has the potential to directly address these diseases as well as the multiple co-morbidities and underlying metabolic dysregulation of NASH.
